No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRSN Mersana Therapeutics
- 2.040
- 0.0000.00%
Close Jun 18 16:00 ET
- 2.000
- -0.040-1.96%
Post 17:51 ET
249.62MMarket Cap-1821P/E (TTM)
2.080High1.995Low1.25MVolume2.040Open2.040Pre Close2.55MTurnover1.66%Turnover RatioLossP/E (Static)122.36MShares6.28052wk High8.91P/B153.52MFloat Cap0.80152wk Low--Dividend TTM75.26MShs Float29.090Historical High--Div YieldTTM4.17%Amplitude0.801Historical Low2.039Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 25%
To the annoyance of some shareholders, Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares are down a considerable 25% in the last month, which continues a horrid run for the company. Instead of being
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis
Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)
Comments
Despite a recent share price hike, Mersana Therapeutics' P/S ratio lags behind others due to forecasted revenue decline. Without major changes, a drastic stock price rise is unlikely.
Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 31% But Its Business Still Trails The IndustryMersana Therapeutics forecasted future revenue decline contributes to lower P/S ratio, limiting strong rise potential in share prices. The market expects performance drop, keeping P/S suppressed. For P/S to avoid further fall, top-line growth needs improvement.
$Mersana Therapeutics(MRSN.US$ some that r buying on cashappyall better load up while u can before they take away the buy button
1
4
$Mersana Therapeutics(MRSN.US$
glad i sold a little on time. lol
glad i sold a little on time. lol
2
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg